CA3070252A1 - Cell penetrating anti-dna binding proteins - Google Patents

Cell penetrating anti-dna binding proteins Download PDF

Info

Publication number
CA3070252A1
CA3070252A1 CA3070252A CA3070252A CA3070252A1 CA 3070252 A1 CA3070252 A1 CA 3070252A1 CA 3070252 A CA3070252 A CA 3070252A CA 3070252 A CA3070252 A CA 3070252A CA 3070252 A1 CA3070252 A1 CA 3070252A1
Authority
CA
Canada
Prior art keywords
seq
sequence
binding protein
cancer
scfv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3070252A
Other languages
English (en)
French (fr)
Inventor
James Campbell
Valentina DUBLJEVIC
James Hansen
Zahra RATTRAY
Jiangbing Zhou
Original Assignee
Nucleus Therapeutics Pty Ltd
Yale University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nucleus Therapeutics Pty Ltd, Yale University filed Critical Nucleus Therapeutics Pty Ltd
Priority to CA3300582A priority Critical patent/CA3300582A1/en
Publication of CA3070252A1 publication Critical patent/CA3070252A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/80—Immunoglobulins specific features remaining in the (producing) cell, i.e. intracellular antibodies or intrabodies
    • C07K2317/82—Immunoglobulins specific features remaining in the (producing) cell, i.e. intracellular antibodies or intrabodies functional in the cytoplasm, the inner aspect of the cell membrane, the nucleus or the mitochondria

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA3070252A 2017-07-17 2018-07-17 Cell penetrating anti-dna binding proteins Pending CA3070252A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA3300582A CA3300582A1 (en) 2017-07-17 2018-07-17 Cell penetrating anti-dna binding proteins

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762533546P 2017-07-17 2017-07-17
US62/533,546 2017-07-17
US201762596694P 2017-12-08 2017-12-08
US62/596,694 2017-12-08
PCT/US2018/042532 WO2019018426A1 (en) 2017-07-17 2018-07-17 BINDING PROTEINS 1

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA3300582A Division CA3300582A1 (en) 2017-07-17 2018-07-17 Cell penetrating anti-dna binding proteins

Publications (1)

Publication Number Publication Date
CA3070252A1 true CA3070252A1 (en) 2019-01-24

Family

ID=65015294

Family Applications (2)

Application Number Title Priority Date Filing Date
CA3070252A Pending CA3070252A1 (en) 2017-07-17 2018-07-17 Cell penetrating anti-dna binding proteins
CA3300582A Pending CA3300582A1 (en) 2017-07-17 2018-07-17 Cell penetrating anti-dna binding proteins

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA3300582A Pending CA3300582A1 (en) 2017-07-17 2018-07-17 Cell penetrating anti-dna binding proteins

Country Status (8)

Country Link
US (5) US11613590B2 (https=)
EP (1) EP3655432A4 (https=)
JP (2) JP7690285B2 (https=)
CN (1) CN111094338A (https=)
AU (1) AU2018302110B2 (https=)
CA (2) CA3070252A1 (https=)
IL (1) IL272064A (https=)
WO (2) WO2019018428A1 (https=)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3597665A1 (en) 2011-04-01 2020-01-22 Yale University, Inc. Cell-penetrating anti-dna antibodies and uses thereof to inhibit dna repair
US12486318B2 (en) 2016-06-15 2025-12-02 Yale University Anti-guanosine antibody as a molecular delivery vehicle
CN109803687B (zh) 2016-06-15 2022-11-15 耶鲁大学 纳米载体向肿瘤的抗体介导的自催化靶向递送
US12304970B2 (en) 2018-02-01 2025-05-20 Yale University Nuclear localization signals, compositions formed therefrom, and methods of use thereof for delivery of cargo to the nucleus
WO2020047345A1 (en) * 2018-08-31 2020-03-05 Yale University Compositions and methods of using cell-penetrating antibodies in combination with immune checkpoint modulators
JP7570107B2 (ja) 2018-08-31 2024-10-21 イェール ユニバーシティー ドナーオリゴヌクレオチドベースの遺伝子編集を亢進するための組成物および方法
AU2020336992A1 (en) 2019-08-30 2022-04-14 Yale University Compositions and methods for delivery of nucleic acids to cells
CA3193424A1 (en) 2020-08-31 2022-03-03 Yale University Compositions and methods for delivery of nucleic acids to cells
CN117295753A (zh) 2020-12-04 2023-12-26 基那奥生物公司 用于将核酸递送到细胞的组合物和方法
US20240216530A1 (en) 2021-03-03 2024-07-04 Yale University Compositions and Methods for Treating Skeletal Muscle Disease
WO2022246511A1 (en) * 2021-05-25 2022-12-01 Transmab Pty Ltd Improved immunoglobulin ii
EP4346907A4 (en) * 2021-05-25 2025-06-25 Transmab Pty Ltd ENHANCED IMMUNOGLOBULIN I
JP2024527322A (ja) 2021-07-02 2024-07-24 イエール ユニバーシティ がんを治療するための組成物および方法
WO2023034864A1 (en) 2021-08-31 2023-03-09 Yale University Compositions and methods for treating cancers
WO2023114887A2 (en) * 2021-12-15 2023-06-22 The Trustees Of Indiana University Cell targeting compositions and methods
WO2023168401A1 (en) 2022-03-03 2023-09-07 Yale University Compositions and methods for treating disease
WO2023168352A1 (en) * 2022-03-03 2023-09-07 Yale University Humanized 3e10 antibodies, variants, and antigen binding fragments thereof
WO2023168427A1 (en) 2022-03-03 2023-09-07 Yale University Compositions and methods for delivering therapeutic polynucleotides for exon skipping
WO2024055034A1 (en) 2022-09-09 2024-03-14 Yale University Proteolysis targeting antibodies and methods of use thereof
KR20250137203A (ko) 2022-12-27 2025-09-17 예일 유니버시티 항체 약물 접합체
WO2024158824A1 (en) 2023-01-23 2024-08-02 Yale University Antibody oligonucleotide conjugates
WO2024197302A1 (en) 2023-03-23 2024-09-26 Yale University Compositions and methods for delivering antibody oligonucleotide conjugates for exon skipping
WO2025049905A1 (en) 2023-09-01 2025-03-06 Gennao Bio, Inc. Dnase co-expression in host cells
WO2025090121A1 (en) * 2023-10-27 2025-05-01 Yale University Conjugate and methods of treatment
WO2025097000A1 (en) 2023-11-01 2025-05-08 Yale University Antibody-based methods for treating polycystic kidney disease
CN121159711A (zh) * 2024-01-02 2025-12-19 河北神宇生物技术有限公司 一种提高adc药物疗效的重组蛋白及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0615662D0 (en) * 2006-08-07 2006-09-13 Affitech As Antibody
US9610362B2 (en) 2012-03-16 2017-04-04 Valerion Therapeutics, Llc Antisense conjugates for decreasing expression of DMPK
US9283272B2 (en) * 2012-03-30 2016-03-15 The United States Of America As Represented By The Department Of Veterans Affairs Targeting intracellular target-binding determinants with intracellular antibodies
EP3094646B1 (en) * 2014-01-13 2020-04-15 Valerion Therapeutics, LLC Internalizing moieties
US10040867B2 (en) * 2014-03-04 2018-08-07 Yale University Cell penetrating anti-guanosine antibody based therapy for cancers with Ras mutations
US10202591B2 (en) * 2014-06-13 2019-02-12 Valerion Therapeutics, Llc Methods and compositions for treatment of glycogen storage diseases and glycogen metabolism disorders
CA2995673A1 (en) 2014-08-27 2016-03-03 Valerion Therapeutics, Llc Internalizing moieties for treatment of cancer
EP3194450A1 (en) 2014-08-28 2017-07-26 Yale University Multivalent fragments of antibody 3e10 and methods of use thereof
US10383945B2 (en) * 2015-02-18 2019-08-20 The United States of America as Represented by the Department of Verterans Affairs Methods for DNA-dependent targeting of a cell permeant antibody

Also Published As

Publication number Publication date
JP2023083385A (ja) 2023-06-15
US20250376540A1 (en) 2025-12-11
WO2019018428A1 (en) 2019-01-24
CA3300582A1 (en) 2026-03-02
US11613590B2 (en) 2023-03-28
US20240052063A1 (en) 2024-02-15
US20230406960A1 (en) 2023-12-21
JP7690285B2 (ja) 2025-06-10
US20200216568A1 (en) 2020-07-09
AU2018302110A1 (en) 2020-02-06
US20200216567A1 (en) 2020-07-09
IL272064A (en) 2020-03-31
CN111094338A (zh) 2020-05-01
AU2018302110B2 (en) 2024-11-21
WO2019018426A1 (en) 2019-01-24
EP3655432A1 (en) 2020-05-27
US12312417B2 (en) 2025-05-27
JP2020527355A (ja) 2020-09-10
EP3655432A4 (en) 2021-04-14

Similar Documents

Publication Publication Date Title
US12312417B2 (en) Binding proteins 1
CN116133694B (zh) 抗her3抗体和抗her3抗体药物偶联物及其医药用途
ES2708124T3 (es) Procedimiento para preparar moléculas heteromultiméricas
US20210380680A1 (en) Anti-claudin antibodies and uses thereof
RU2708075C2 (ru) Конъюгаты анти-ртк7 антитело-лекарственное средство
JP6326137B2 (ja) 抗ｈｅｒ２抗体及びその結合体
TW202136314A (zh) 抗ｃｃｒ８抗體及其用途
JP7366886B2 (ja) Ａｘｌ特異的抗体及びその使用
KR101820029B1 (ko) 암의 예방 및/또는 치료에서 사용하기 위한 방사성 표지 항체 단편
TW201643195A (zh) 對細胞內致癌基因產物的單株抗原結合蛋白
WO2017196764A1 (en) Antibody-drug conjugate of an anti-glypican-3 antibody and a tubulysin analog, preparation and uses
JP2026065117A (ja) 最適化された薬物コンジュゲーションのための改変された結合ポリペプチド
KR20260046386A (ko) 인간화 muc1 항체 및 항체 약물 접합체
TW202432185A (zh) 配體－細胞毒性藥物綴合物及其藥物用途
JP2022541765A (ja) 抗ｇｒｐ７８抗体およびその使用方法
US20240270851A1 (en) Cross species single domain antibodies targeting pd-l1 for treating solid tumors
Steiner Targeted delivery of cytotoxic agents: direct conjugation to antibodies and pretargeting approaches
HK40122548A (zh) 抗cd44v6抗体及其用於治疗cd44v6过表达癌症的用途
TW201711702A (zh) 使用針對纖維母細胞生長因子受體３（ｆｇｆｒ３）之化合物的療法
TW202417054A (zh) 配體－細胞毒性藥物偶聯物及其藥物用途
TW202432186A (zh) 配體-細胞毒藥物綴合物及其醫藥用途
EA052523B1 (ru) Антитела против cd44v6 и их использование для лечения онкологических заболеваний, характеризующихся гиперэкспрессией cd44v6
HK40100135A (zh) 结合trop2的抗体及其用途
HK40120932A (zh) 抗体及其药物偶联物和用途
HK40064761B (zh) 抗cd228抗体和抗体-药物缀合物

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220928

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20241018

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250130

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250130

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D149 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S INTERVIEW

Effective date: 20250508

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20250522

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250523

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD

Year of fee payment: 7

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250527

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250527

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250610

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250610